反映宿主反应的血浆蛋白生物标志物在发生重症监护室获得性肺炎患者中的表现
该研究为巢式病例对照研究,纳入11个欧洲国家30家医院ICU机械通气且预期停留至少48小时的患者,共1997例,其中316例(15.8%)发生肺炎,1681例(84.2%)未发生。在病例和随机选取的对照组(与病例1:2比例,n=632)中检测19种反映宿主反应的生物标志物,于入组时和入组第7天采集血浆,病例另在肺炎诊断当天采集。结果显示病例在入组时(ICU入住后中位2天)及走向肺炎诊断过程中(ICU入住后中位5天)表现出提示炎症增强和内皮屏障功能更紊乱的标志物浓度。基线宿主反应标志物异常在ICU入住后早期(<5天,n=105)或晚期(>10天,n=68)发生肺炎的患者中最为显著。结论认为发生ICU获得性肺炎的重症患者相比未发生者,血浆蛋白标志物浓度改变提示更强的促炎、促凝和(损伤性)内皮细胞反应。
要点
- 1997例机械通气患者中316例(15.8%)发生ICU获得性肺炎,1681例(84.2%)未发生。
- 病例在入组时(ICU入住后中位2天)即显示提示炎症增强和内皮屏障功能更紊乱的标志物浓度。
- 在走向肺炎诊断过程中(ICU入住后中位5天),病例同样显示上述标志物改变。
- 基线宿主反应标志物异常在早期(<5天,n=105)或晚期(>10天,n=68)发生肺炎者中最显著。
- 研究检测19种反映关键病理生理领域的宿主反应标志物,病例与随机对照组按1:2比例(n=632)比较。
适用人群与场景
- ICU入院时接受机械通气且预期停留至少48小时的患者,来自11个欧洲国家30家医院。
研究设计与关键结果
- 研究类型为巢式病例对照研究,纳入1997例机械通气患者,其中316例(15.8%)发生肺炎,1681例(84.2%)未发生。
- 在病例和随机选取的对照组(与病例1:2比例,n=632)中检测19种反映宿主反应的血浆蛋白生物标志物,于入组时和入组第7天采集,病例另在肺炎诊断当天采集。
- 病例在入组时(ICU入住后中位2天)显示提示炎症增强和内皮屏障功能更紊乱的标志物浓度。
- 病例在走向肺炎诊断过程中(ICU入住后中位5天)同样显示提示炎症增强和内皮屏障功能更紊乱的标志物浓度。
- 基线宿主反应标志物异常在ICU入住后早期(<5天,n=105)或晚期(>10天,n=68)发生肺炎的患者中最为显著。
- 结论认为发生ICU获得性肺炎的重症患者相比未发生者,血浆蛋白标志物浓度改变提示更强的促炎、促凝和(损伤性)内皮细胞反应。
证据类型、等级与局限
- 证据类型:巢式病例对照研究。
- 试验注册:ClinicalTrials.gov Identifier: NCT02413242,2015年4月9日发布。
- 局限:原文未报告局限性。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「对床旁实践的改变」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Immune suppression has been implicated in the occurrence of pneumonia in critically ill patients. We tested the hypothesis that Intensive Care Unit (ICU)-acquired pneumonia is associated with broad host immune aberrations in the trajectory to pneumonia, encompassing inflammatory, endothelial and coagulation responses. We compared plasma protein biomarkers reflecting the systemic host response in critically ill patients who acquire a new pneumonia (cases) with those who do not (controls).
METHODS: We performed a nested case-control study in patients undergoing mechanical ventilation at ICU admission with an expected stay of at least 48 h enrolled in 30 hospitals in 11 European countries. Nineteen host response biomarkers reflective of key pathophysiological domains were measured in plasma obtained on study inclusion and day 7, and-in cases-on the day of pneumonia diagnosis.
RESULTS: Of 1997 patients, 316 developed pneumonia (15.8%) and 1681 did not (84.2%). Plasma protein biomarker analyses, performed in cases and a randomly selected subgroup of controls (1:2 ratio to cases, n = 632), demonstrated considerable variation across time points and patient groups. Yet, cases showed biomarker concentrations suggestive of enhanced inflammation and a more disturbed endothelial barrier function, both at study enrollment (median 2 days after ICU admission) and in the path to pneumonia diagnosis (median 5 days after ICU admission). Baseline host response biomarker aberrations were most profound in patients who developed pneumonia either shortly (< 5 days, n = 105) or late (> 10 days, n = 68) after ICU admission.
CONCLUSIONS: Critically ill patients who develop an ICU-acquired pneumonia, compared with those who do not, display alterations in plasma protein biomarker concentrations indicative of stronger proinflammatory, procoagulant and (injurious) endothelial cell responses.
TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02413242, posted April 9th, 2015.
参考来源
- van Engelen TSR, Reijnders TDY, Paling FP, et al. Plasma protein biomarkers reflective of the host response in patients developing Intensive Care Unit-acquired pneumonia. Crit Care. 2023. PMID: 37415223. doi:10.1186/s13054-023-04536-0
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。